Skip to main
IMTX
IMTX logo

Immatics NV (IMTX) Stock Forecast & Price Target

Immatics NV (IMTX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immatics NV's ACTengine platform showcases enhanced logistics compared to existing solid tumor cell therapies, potentially streamlining production and administration processes. The company is positioned to achieve significant monotherapy activity, with a target of at least a 20% overall response rate (ORR) and a minimum progression-free survival (mPFS) duration of four months, which could strengthen investor confidence in its therapeutic offerings. Additionally, positive responses are anticipated to increase with higher dose levels, further supporting Immatics's potential for strong clinical outcomes and revenue growth in the oncology market.

Bears say

Immatics NV's stock outlook is negatively affected by the underwhelming clinical data from Brenetafusp presented at ASCO '24, which reported only an 11% overall response rate (ORR) and a 56% disease control rate (DCR) among second-line melanoma patients. The company's risk profile includes significant R&D, regulatory, and commercial challenges, potential competition, and the prospects of lower-than-expected sales combined with dilutive financing, which may exceed prior assumptions. Furthermore, a downside scenario predicts a valuation drop to approximately $3 per share if key pipeline programs, including SUPRAME and others, fail to meet critical milestones or deliver disappointing updates.

Immatics NV (IMTX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immatics NV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immatics NV (IMTX) Forecast

Analysts have given Immatics NV (IMTX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Immatics NV (IMTX) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immatics NV (IMTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.